| Trial Name: |
CASE 1205
|
| Intro: |
Dose-Dense and Dose-Intense Alternating Irinotecan/Capecitabine and Oxaliplatin/Capecitabine: Phase I in Solid Tumors and Phase II with Bevacizumab as First-Line Therapy of Advanced Colorectal Cancer |
| Condition: |
|
| Description: |
This study will determine the maximum tolerated dose of Oxaliplatin, Irinotecan, and Capecitabine when given every 2 weeks, and determine if they will lead to improved response rates as first line therapy of advanced colorectal cancer. |
| Criteria: |
- Age > 18 years
- Phase I: Patients must have a histologically confirmed solid tumor cancer which is metastatic or locally advanced and unresectable, Phase II: Patients must have advanced colorectal cancer
- Life expectancy > 12 weeks
- Patients must have normal bone marrow, liver and kidney function
|
| Contact: |
For Cancer Information, Current Clinical Trials, and Referral to a Physician please call (216) 844-5432 or (800) 641-2422 |
Participant Confidentiality:
All information regarding participation in Clinical Trials is treated with the
utmost confidentiality. University Hospitals Case Medical Center and the
Division of Clinical Research recognize and respect the confidentiality of this
information. Access to information related to clinical trials and their
participants is restricted to authorized clinical trials personnel only.
Back